Achilles Therapeutics sells technology assets to AstraZeneca for $12M, ending strategic review

From GlobeNewswire: 2024-12-24 09:30:00

Achilles Therapeutics plc has transferred data and samples from the TRACERx NSCLC study to AstraZeneca. AstraZeneca will also take over Achilles’ Material Acquisition Platform. AstraZeneca will pay Achilles $12M for the assets. The conclusion of this transaction marks the end of Achilles’ strategic review, leading to further measures including employee headcount and Board of Directors reductions. TRACERx, led by Professor Charles Swanton at UCL, is a groundbreaking tumor evolution study that sheds light on cancer evolution and immune evasion mechanisms. The study has led to the identification of clonal neoantigens as ideal cancer targets.



Read more at GlobeNewswire: Achilles Therapeutics Announces Sale of Technology Assets